Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 363 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: LDL Clear all

Conditions: Work-related Injury
Interventions: Motivational Interview (MI), Participatory Group Activity, Control Condition; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: Blood Draw; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hyperlipidemia
Interventions: SLx-4090, Placebo, Statin; Drug · Other
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Cardiovascular Risk Factor
Interventions: Plant Sterol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Low Phytosterol and High Phytosterol Diets; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Dyslipidaemia
Interventions: AZD8233, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Roseville, California • Inverness, Florida • Jacksonville, Florida + 7 more

Conditions: Coronary Artery Disease
Interventions: Rosuvastatin, Colchicine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fatty Liver, Hepatitis
Interventions: Orlistat (Xenical), 1400 kcal diet (30% fat); Drug · Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: St Louis, Missouri • San Antonio, Texas

Conditions: Hyperlipidemia
Interventions: Plasmapharesis; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 20 more

Conditions: Hypercholesterolemia
Interventions: Vytorin, Simvastatin; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections, Lipodystrophy
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Hypercholesterolemia
Interventions: LY3015014, Placebo, Statin, Ezetimibe; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Encino, California • Lancaster, California • Spring Valley, California + 12 more

Conditions: Macular Edema, Diabetes Mellitus
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Normal Glucose Metabolism, Hyperlipidemia
Interventions: fasting 12+ hours, Non-fasting; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Hypercholesterolemia
Interventions: secoisolariciresinol diglucoside-containing extract of flaxseed; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Hypolipoproteinemia, Hypercholesterolemia, Dyslipidemia, Hyperlipidemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1976
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: lerodalcibep, evolocumab; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 10 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Evanston, Illinois • Cincinnati, Ohio

Conditions: Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions: Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions; Dietary Supplement · Other
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Prevention Program to Reduce Injury Disparities Among Latino Day Laborers

Validation of an RLIP76 Assay in Humans

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism

A Study of AZD8233 in Participants With Dyslipidemia

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

Acute Microvascular Changes With LDL Apheresis

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

A Study of LY3015014 in Participants With High Cholesterol

Laser and Antioxidant Treatment of Diabetic Macular Edema

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Flax Lignans and Heart Health

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health